Real-World Outcomes in Patients with EGFR/ALK-Positive NSCLC Treated with Chemotherapy Following 1 or 2 Lines of TKI Therapy

被引：0
|
作者：
Cheema, P. [1 ]
Ton, T. [2 ]
Lambert, P. [2 ]
Merritt, D. [3 ]
Morris, S. [3 ]
Shankar, G. [2 ]
Ganti, A. K. [4 ,5 ]
机构：
[1] Univ Toronto, William Osler Hlth Syst, Toronto, ON, Canada
[2] Genentech Inc, San Francisco, CA 94080 USA
[3] F Hoffmann La Roche Ltd, Basel, Switzerland
[4] VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA
[5] Univ Nebraska Med Ctr, Omaha, NE USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TT01.01
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [1] Outcomes of Early Stage ALK-positive NSCLC patients in a Real-World Cohort
    Schmid, S.
    Chotai, S.
    Cheng, S.
    Zhan, L.
    Balaratnam, K.
    Khan, K.
    Patel, D.
    Brown, M. C.
    Xu, W.
    Moriarty, P.
    Kaidanovich-Beilin, O.
    Shepherd, F. A.
    Sacher, A.
    Leighl, N.
    Bradbury, P.
    Liu, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S908 - S909
  • [2] ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
    Moskovitz, Mor
    Dudnik, Elizabeth
    Shamai, Sivan
    Rotenberg, Yakir
    Popovich-Hadari, Noa
    Wollner, Mira
    Zer, Alona
    Gottfried, Maya
    Mishaeli, Moshe
    Rosenberg, Shoshana Keren
    Onn, Amir
    Merimsky, Ofer
    Urban, Damien
    Peled, Nir
    Maimon, Natalie
    Bar, Jair
    ONCOLOGIST, 2022, 27 (01): : E76 - E84
  • [3] Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada
    Chotai, S.
    Schmid, S.
    Cheng, S.
    Zhan, L.
    Balaratnam, K.
    Khan, K.
    Patel, D.
    Brown, M. C.
    Xu, W.
    Moriarty, P.
    Kaidanovich-Beilin, O.
    Shepherd, F. A.
    Sacher, A.
    Leighl, N.
    Bradbury, P.
    Liu, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1089 - S1089
  • [4] Therapeutic effectiveness of Lorlatinib After Alectinib in Japanese Patients With ALK-Positive NSCLC in Real-World
    Goto, Y.
    Emir, B.
    Kaneyasu, K.
    Kikkawa, H.
    Wiltshire, R.
    Shukuya, T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1084 - S1084
  • [5] Real-World Treatment Sequencing and Impact on Outcomes in ALK-Positive (ALK plus ) NoneSmall Cell Lung Cancer (NSCLC)
    Wan, Y.
    Elliott, J.
    Young, M.
    Yin, Y.
    Arnaoutakis, K.
    Leventakos, K.
    Lin, H. M.
    Dimou, A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E33 - E34
  • [6] Real World Utilization and Outcomes of ALK-Positive Crizotinib Treated Metastatic NSCLC Patients in US Community Oncology Practice
    Reynolds, Craig
    Masters, Elizabeth
    Black-Shinn, Jenny
    Mardekian, Jack
    Espirito, Janet
    Boyd, Marley
    Chioda, Marc
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1172 - S1173
  • [7] Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK plus NSCLC
    Arnaoutakis, Konstantinos
    Wan, Yin
    Elliott, Jennifer
    Young, Matt
    Yin, Yu
    Leventakos, Konstantinos
    Lin, Huamao M.
    Dimou, Anastasios
    ADVANCES IN THERAPY, 2024, 41 (08) : 3217 - 3231
  • [8] Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib
    Davis, K. L.
    Kaye, J. A.
    Masters, E. T.
    Iyer, S.
    CURRENT ONCOLOGY, 2018, 25 (01) : E40 - E49
  • [9] Response Rate and Outcomes in Crizotinib Treated Advanced ALK-Positive NSCLC Patients
    Davis, Keith L.
    Kaye, James A.
    Iyer, Shrividya
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S411 - S412
  • [10] Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC.
    Riely, Gregory J.
    Lovly, Christine Marie
    Messina, Carlo G. M.
    Bienert, Stefanie
    Alexander, Kimberly
    Pao, William
    Baxi, Shrujal
    Doebele, Robert Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345